The Emerging Role of N6-Methyladenosine RNA Methylation As Regulators in Cancer Therapy and Drug Resistance

Overview

Journal Front Pharmacol

Date 2022 Apr 25

PMID 35462896

Authors

Zhaolin Chen

Ying Hu

Le Jin

Fan Yang

Haiwen Ding

Lei Zhang

Lili Li

Tingting Pan

Affiliations

Soon will be listed here.

Abstract

N6-methyladenosine (mA) RNA methylation has been considered the most prevalent, abundant, and conserved internal transcriptional modification throughout the eukaryotic mRNAs. Typically, mA RNA methylation is catalyzed by the RNA methyltransferases (writers), is removed by its demethylases (erasers), and interacts with mA-binding proteins (readers). Accumulating evidence shows that abnormal changes in the mA levels of these regulators are increasingly associated with human tumorigenesis and drug resistance. However, the molecular mechanisms underlying mA RNA methylation in tumor occurrence and development have not been comprehensively clarified. We reviewed the recent findings on biological regulation of mA RNA methylation and summarized its potential therapeutic strategies in various human cancers.

Citing Articles

Writers, readers, and erasers RNA modifications and drug resistance in cancer.

Chen D, Gu X, Nurzat Y, Xu L, Li X, Wu L Mol Cancer. 2024; 23(1):178.

PMID: 39215288 PMC: 11363509. DOI: 10.1186/s12943-024-02089-6.

PRMT6-mediated transcriptional activation of ythdf2 promotes glioblastoma migration, invasion, and emt via the wnt-β-catenin pathway.

Yu P, Xu T, Ma W, Fang X, Bao Y, Xu C J Exp Clin Cancer Res. 2024; 43(1):116.

PMID: 38637831 PMC: 11025288. DOI: 10.1186/s13046-024-03038-3.

Disruption of the mouse liver epitranscriptome by long-term aroclor 1260 exposure.

Piell K, Petri B, Head K, Wahlang B, Xu R, Zhang X Environ Toxicol Pharmacol. 2023; 100:104138.

PMID: 37137421 PMC: 10330322. DOI: 10.1016/j.etap.2023.104138.

Epigenetic Targets and Their Inhibitors in Thyroid Cancer Treatment.

Zhang K, Wang J, He Z, Qiu X, Sa R, Chen L Pharmaceuticals (Basel). 2023; 16(4).

PMID: 37111316 PMC: 10142462. DOI: 10.3390/ph16040559.

The Epitranscriptomic Mechanism of Metal Toxicity and Carcinogenesis.

Yang C, Wang Z Int J Mol Sci. 2022; 23(19).

PMID: 36233132 PMC: 9569618. DOI: 10.3390/ijms231911830.

References

Dai X, Shi L, Li Z, Yang H, Wei J, Ding Q . Main N6-Methyladenosine Readers: YTH Family Proteins in Cancers. Front Oncol. 2021; 11:635329. PMC: 8076607. DOI: 10.3389/fonc.2021.635329. View

Huang H, Wang Y, Kandpal M, Zhao G, Cardenas H, Ji Y . FTO-Dependent -Methyladenosine Modifications Inhibit Ovarian Cancer Stem Cell Self-Renewal by Blocking cAMP Signaling. Cancer Res. 2020; 80(16):3200-3214. PMC: 7442742. DOI: 10.1158/0008-5472.CAN-19-4044. View

Rong D, Dong Q, Qu H, Deng X, Gao F, Li Q . mA-induced LINC00958 promotes breast cancer tumorigenesis via the miR-378a-3p/YY1 axis. Cell Death Discov. 2021; 7(1):27. PMC: 7854648. DOI: 10.1038/s41420-020-00382-z. View

Hu J, Cai D, Zhao Z, Zhong G, Gong J . Suppression of Heterogeneous Nuclear Ribonucleoprotein C Inhibit Hepatocellular Carcinoma Proliferation, Migration, and Invasion Ras/MAPK Signaling Pathway. Front Oncol. 2021; 11:659676. PMC: 8087488. DOI: 10.3389/fonc.2021.659676. View

Tanabe A, Tanikawa K, Tsunetomi M, Takai K, Ikeda H, Konno J . RNA helicase YTHDC2 promotes cancer metastasis via the enhancement of the efficiency by which HIF-1α mRNA is translated. Cancer Lett. 2016; 376(1):34-42. DOI: 10.1016/j.canlet.2016.02.022. View

Hsu P, Zhu Y, Ma H, Guo Y, Shi X, Liu Y . Ythdc2 is an N-methyladenosine binding protein that regulates mammalian spermatogenesis. Cell Res. 2017; 27(9):1115-1127. PMC: 5587856. DOI: 10.1038/cr.2017.99. View

Xu Y, Ye S, Zhang N, Zheng S, Liu H, Zhou K . The FTO/miR-181b-3p/ARL5B signaling pathway regulates cell migration and invasion in breast cancer. Cancer Commun (Lond). 2020; 40(10):484-500. PMC: 7571404. DOI: 10.1002/cac2.12075. View

Zhang C, Huang S, Zhuang H, Ruan S, Zhou Z, Huang K . YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation. Oncogene. 2020; 39(23):4507-4518. DOI: 10.1038/s41388-020-1303-7. View

Ni H, Zhang L, Huang H, Dai S, Li J . Connecting METTL3 and intratumoural CD33 MDSCs in predicting clinical outcome in cervical cancer. J Transl Med. 2020; 18(1):393. PMC: 7565373. DOI: 10.1186/s12967-020-02553-z. View

10.

Zhang Z, Chen L, Zhao Y, Yang C, Roundtree I, Zhang Z . Single-base mapping of mA by an antibody-independent method. Sci Adv. 2019; 5(7):eaax0250. PMC: 6609220. DOI: 10.1126/sciadv.aax0250. View

11.

Shi R, Ying S, Li Y, Zhu L, Wang X, Jin H . Linking the YTH domain to cancer: the importance of YTH family proteins in epigenetics. Cell Death Dis. 2021; 12(4):346. PMC: 8016981. DOI: 10.1038/s41419-021-03625-8. View

12.

Nie S, Zhang L, Liu J, Wan Y, Jiang Y, Yang J . ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer. J Exp Clin Cancer Res. 2021; 40(1):284. PMC: 8425158. DOI: 10.1186/s13046-021-02088-1. View

13.

Dixit D, Prager B, Gimple R, Poh H, Wang Y, Wu Q . The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells. Cancer Discov. 2020; 11(2):480-499. PMC: 8110214. DOI: 10.1158/2159-8290.CD-20-0331. View

14.

Li Q, Huang Y, Liu X, Gan J, Chen H, Yang C . Rhein Inhibits AlkB Repair Enzymes and Sensitizes Cells to Methylated DNA Damage. J Biol Chem. 2016; 291(21):11083-93. PMC: 4900258. DOI: 10.1074/jbc.M115.711895. View

15.

Huang W, Chen T, Fang K, Zeng Z, Ye H, Chen Y . N6-methyladenosine methyltransferases: functions, regulation, and clinical potential. J Hematol Oncol. 2021; 14(1):117. PMC: 8313886. DOI: 10.1186/s13045-021-01129-8. View

16.

Wang C, Gu Y, Zhang E, Zhang K, Qin N, Dai J . A cancer-testis non-coding RNA LIN28B-AS1 activates driver gene LIN28B by interacting with IGF2BP1 in lung adenocarcinoma. Oncogene. 2018; 38(10):1611-1624. DOI: 10.1038/s41388-018-0548-x. View

17.

Yang Z, Yang S, Cui Y, Wei J, Shah P, Park G . METTL14 facilitates global genome repair and suppresses skin tumorigenesis. Proc Natl Acad Sci U S A. 2021; 118(35). PMC: 8536359. DOI: 10.1073/pnas.2025948118. View

18.

Wanna-Udom S, Terashima M, Lyu H, Ishimura A, Takino T, Sakari M . The m6A methyltransferase METTL3 contributes to Transforming Growth Factor-beta-induced epithelial-mesenchymal transition of lung cancer cells through the regulation of JUNB. Biochem Biophys Res Commun. 2020; 524(1):150-155. DOI: 10.1016/j.bbrc.2020.01.042. View

19.

Mitchell K, Troike K, Silver D, Lathia J . The evolution of the cancer stem cell state in glioblastoma: emerging insights into the next generation of functional interactions. Neuro Oncol. 2020; 23(2):199-213. PMC: 7906055. DOI: 10.1093/neuonc/noaa259. View

20.

Jin D, Guo J, Wu Y, Yang L, Wang X, Du J . mA demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2-mediated YAP activity in NSCLC. Mol Cancer. 2020; 19(1):40. PMC: 7045432. DOI: 10.1186/s12943-020-01161-1. View